Expression Profile of Selected MicroRNAs in the Peripheral Blood of Multiple Sclerosis Patients: a Multivariate Statistical Analysis with ROC Curve to Find New Biomarkers for Fingolimod
- PMID: 30895441
- DOI: 10.1007/s12031-019-01294-z
Expression Profile of Selected MicroRNAs in the Peripheral Blood of Multiple Sclerosis Patients: a Multivariate Statistical Analysis with ROC Curve to Find New Biomarkers for Fingolimod
Abstract
Multiple sclerosis (MS) as a chronic autoimmune disease of the central nervous system (CNS) has been associated with dysregulation of several genes including miRNAs. In the present study, we assessed transcript levels of seven miRNAs (miR-96-5p, miR-211-5p, miR-15a, miR-34a-5p, miR-204-5p, miR-501-5p, and miR-524-5p) in the peripheral blood of MS patients compared with healthy subjects in association with response to fingolimod treatment. Expression levels of miR-211-5p and miR-34a-5p were significantly decreased in MS patients compared with healthy subjects (P values of 0.002 and 0.47). While subgroup analysis showed downregulation of miR-211-5p in both fingolimod responders and non-responders, miR-34a-5p expression was only decreased in responders. Moreover, miR-204-5p was downregulated in non-responder male patients compared with male controls. The current study underscores the role of miRNAs in determination of response to fingolimod in MS patients.
Keywords: Fingolimod; Multiple sclerosis; miRNA.
Similar articles
-
Assessment of expression profile of microRNAs in multiple sclerosis patients treated with fingolimod.J Mol Neurosci. 2020 Aug;70(8):1274-1281. doi: 10.1007/s12031-020-01537-4. Epub 2020 Mar 25. J Mol Neurosci. 2020. PMID: 32215780
-
Effect of fingolimod treatment on circulating miR-15b, miR23a and miR-223 levels in patients with multiple sclerosis.J Neuroimmunol. 2016 Oct 15;299:81-83. doi: 10.1016/j.jneuroim.2016.08.017. Epub 2016 Aug 31. J Neuroimmunol. 2016. PMID: 27725128
-
Serum Exosome MicroRNAs Predict Multiple Sclerosis Disease Activity after Fingolimod Treatment.Mol Neurobiol. 2020 Feb;57(2):1245-1258. doi: 10.1007/s12035-019-01792-6. Epub 2019 Nov 12. Mol Neurobiol. 2020. PMID: 31721043
-
Multiple sclerosis treatment with fingolimod: profile of non-cardiologic adverse events.Acta Neurol Belg. 2017 Dec;117(4):821-827. doi: 10.1007/s13760-017-0794-7. Epub 2017 May 20. Acta Neurol Belg. 2017. PMID: 28528469 Review.
-
Potential neuroprotective effect of Fingolimod in multiple sclerosis and its association with clinical variables.Expert Opin Pharmacother. 2018 Mar;19(4):387-395. doi: 10.1080/14656566.2018.1434143. Epub 2018 Feb 3. Expert Opin Pharmacother. 2018. PMID: 29397790 Review.
Cited by
-
Multiple Sclerosis: Melatonin, Orexin, and Ceramide Interact with Platelet Activation Coagulation Factors and Gut-Microbiome-Derived Butyrate in the Circadian Dysregulation of Mitochondria in Glia and Immune Cells.Int J Mol Sci. 2019 Nov 5;20(21):5500. doi: 10.3390/ijms20215500. Int J Mol Sci. 2019. PMID: 31694154 Free PMC article. Review.
-
MicroRNAs as a possible biomarker in the treatment of multiple sclerosis.IBRO Neurosci Rep. 2022 Nov 7;13:492-499. doi: 10.1016/j.ibneur.2022.11.001. eCollection 2022 Dec. IBRO Neurosci Rep. 2022. PMID: 36439971 Free PMC article. Review.
-
Bayesian multilevel model of micro RNA levels in ovarian-cancer and healthy subjects.PLoS One. 2019 Aug 29;14(8):e0221764. doi: 10.1371/journal.pone.0221764. eCollection 2019. PLoS One. 2019. PMID: 31465488 Free PMC article.
-
Ceramide and Sphingosine Regulation of Myelinogenesis: Targeting Serine Palmitoyltransferase Using microRNA in Multiple Sclerosis.Int J Mol Sci. 2019 Oct 11;20(20):5031. doi: 10.3390/ijms20205031. Int J Mol Sci. 2019. PMID: 31614447 Free PMC article. Review.
-
miRNAs in Microglia: Important Players in Multiple Sclerosis Pathology.ASN Neuro. 2021 Jan-Dec;13:1759091420981182. doi: 10.1177/1759091420981182. ASN Neuro. 2021. PMID: 33517686 Free PMC article. Review.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical